LLY241129P970000
- 81.03
- 0.000.00%
Eli Lilly and Co Newsroom
Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ
S&P 500 Posts Weekly Rise to Fresh Record, Ends November With Strongest Monthly Gain of Year
10 Health Care Stocks With Whale Alerts In Today's Session
Trump 'sells off' European pharmaceutical stocks, can only rely on 'Americanization' to stop the decline?
The growth prescription for European pharmaceutical companies: shifting towards the usa.
Behind the Scenes of Eli Lilly's Latest Options Trends
Jefferies Financial: Trump's return is bullish for growth stocks, with the top 10 having the greatest upside.
Jefferies financial strategists expect that Trump's re-election as president will encourage investors to continue pursuing growth stocks, suggesting that investors avoid value stocks.
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Express News | In the first 10 months of this year, the number of newly established foreign-funded enterprises in peking increased by 13.3% year-on-year.
The Trump economic team may have internal discord, and the key agenda still needs the "understanding king" to make the final decision!
Analysts state that the Trump team's characterization of the economic policy as 'the opponent team' is almost accurate, and the strong opposition between Besant and Lutnik has been publicly reported.
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
U.S. stocks early market | Core PCE has the largest increase since April of this year! Spot gold briefly dropped; quantum computing concept stocks are booming! QUBT and RGTI rose by 10%, and Quantum once triggered a circuit breaker.
The market continues to focus on Trump's tariff policy and cabinet composition. The actual GDP growth rate of the United States in the third quarter slowed down compared to the second quarter.
Eli Lilly's Flortaucipir Approved by UK Regulator to Test for Alzheimer's Disease
LLY, NVO Stock Up as Biden Proposes Medicare Cover for Obesity Drugs
Express News | Mhra: Approves Flortaucipir (Tauvid) for Adults Showing Signs of Cognitive Impairment for Alzheimer’s Disease
Erste Group Downgrades Eli Lilly and Co(LLY.US) to Hold Rating
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,000
US stocks unusual movement | Amgen continued to fall by more than 2.6% before the market opened, announcing that the weight loss drug trial effect is comparable to eli lilly and co's Zepbound but with more side effects.
Glonghui, November 27 - Amgen (AMGN.US) continued to decline more than 2.6% in pre-market trading, reporting $272.64. The stock fell 4.76% on Tuesday. In terms of news, Amgen announced on Tuesday that in a year-long trial, non-diabetic patients taking the weight loss drug MariTide once a month or less could lose up to 20% of their weight. Analysts pointed out that this is comparable to the effects of Eli Lilly and Co's Zepbound at its highest dose. However, data shows that the side effects of MariTide are greater than those of Zepbound, with about 11% of patients dropping out due to side effects.
Is weight loss medication including in usa medical insurance, becoming the strongest 'roadblock' for the Trump team?
"Weight loss duo" leads significant increase.
Hong Kong stocks move | Laika Pharmaceutical-B (02105) rose more than 11% in early trading. Overnight, U.S. stocks in the weight loss drugs sector experienced a broad rise. The company has launched clinical cooperation with eli lilly and co on a new weigh
Lai Kai Pharmaceutical-B (02105) rose more than 11% in the morning, as of the time of publication, it increased by 9.79%, reaching 17.04 Hong Kong dollars, with a turnover of 30.7419 million Hong Kong dollars.